Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

508.77
-7.9700-1.54%
Volume:19.28K
Turnover:9.86M
Market Cap:11.73B
PE:-35.79
High:517.00
Open:517.00
Low:507.76
Close:516.74
52wk High:615.00
52wk Low:393.61
Shares:23.06M
Float Shares:13.73M
Volume Ratio:0.35
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.2164
EPS(LYR):-12.8501
ROE:-53.31%
ROA:-17.84%
PB:22.40
PE(LYR):-39.59

Loading ...

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades

Simply Wall St.
·
Jun 06

Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan

Reuters
·
Jun 05

Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 05

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?

Simply Wall St.
·
Jun 04

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

GlobeNewswire
·
Jun 03

Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08

Reuters
·
Jun 02

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data

Simply Wall St.
·
May 29

Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data

TIPRANKS
·
May 28

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients With Mash

THOMSON REUTERS
·
May 27

Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)

TIPRANKS
·
May 26

Madrigal director Richard S. Levy disposes of USD 2.4 million common shares

Reuters
·
May 23

Madrigal Pharmaceuticals grants 5,308 inducement RSUs to 15 new employees

Reuters
·
May 22

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 22

Madrigal Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
May 13

Truist Raises Price Target on Madrigal Pharmaceuticals to $709 From $640, Keeps Buy Rating

MT Newswires Live
·
May 13

BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings

Reuters
·
May 13

BUZZ-Truist raises PT on Madrigal Pharma on liver disease drug opportunity

Reuters
·
May 13

Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
May 13

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals

Simply Wall St.
·
May 11